SEARCH

SEARCH BY CITATION

LITERATURE CITED

  • 1
    Libby P. Role of inflammation on artherosclerosis associated with rheumatoid arthritis. Am J Med 2008; 121 ( Suppl. 1): S21S31.
  • 2
    Heimburger N. Proteinase inhibitors of human plasma - their properties and control functions. In: Reich E,Rifkin DB,Shaw E, editors. Proteases and Biological Control. Cold Spring Harbor: Cold Spring Harbor Laboratory; 1975. p 367404.
  • 3
    Wewers MD,Herzyk DJ,Gadek JE. Alveolar fluid neutrophil elastase activity in the adult respiratory distress sysndrome is complexed to alpha-2-macroglobulin. J. Clin Invest 1988; 82: 12601267.
  • 4
    Reh G,Nerli B,Pico G. Isolation of alpha-1-antitrypsin from human plasma by partitioning in aqueous biphasic systems of polyethyleneglycol-phosphate. J Chromatogr B 2002; 780: 389396.
  • 5
    Abbink JJ,Kamp AM,Nuijens JH,Swaak TJG,Hack CE. Proteolytic inactivation of α1-antitrypsin and α1-antichymotrypsin by neutrophils in arthritic joints. Arthritis Rheum 1993; 36: 168180.
  • 6
    Vissers MC,George PM,Bathurst IC,Brennan SO,Winterbourn CC. Cleavage and inactivation of alpha 1-antitrypsin by metalloproteinases released from neutrophils. J Clin Invest 1988; 82: 706711.
  • 7
    Tirado-Conde G,Lara B,Miravittles M. Augmentation therapy for emphysema due to alpha-1-antitrypsin defiency. Ther Adv Respir Dis 2008; 2: 1321.
  • 8
    Doan T,Massarotti E. Rheumatoid arthritis: an overview of new and emerging therapy. J Clin Pharmacol 2005; 45: 751762.
  • 9
    Chung CP,Avalos I,Raggi P,Stein CP. Atherosclerosis and inflammation: Insights from rheumatoid arthritis. Clin Rheumatol 2007; 26: 12281233.
  • 10
    Dubertret L. Retinoids, methotrexate and cyclosporine. Curr Probl Dermatol 2009; 38: 7994.
  • 11
    Heitz F,Morris MC,Divita G. Themed section: Vector design and drug delivery, review, twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol 2009; 157: 195206.
  • 12
    Rennert R,Neundorf I,Beck-Sickinger AG. Calcitonin-derived peptide carriers: Mechanisms and application. Adv Drug Deliv Rev 2008; 60: 485498.
  • 13
    Rennert R,Neundorf I,Jahnke HG,Suchowerskyj P,Dournaud P,Robitzki A,Beck-Sickinger AG. Generation of carrier peptides for the delivery of nucleic acid drugs in primary cells. Chem Med Chem 2008; 3: 241253.
  • 14
    Dallegri F,Dapino P,Arduino N,Bertolotto M,Ottonello L. Cefoperazone prevents the inactivation of alpha(1)-antitrypsin by activated neutrophils. Antimicrob Agents Chemother 1999; 43; 23012310.
  • 15
    Böyum A. Separation of leucocytes from blood and bone marrow. Scand J Clin Lab Invest Suppl 1968; 21: 729.
  • 16
    Glander HJ,Schaller J. Binding of annexin V to plasma membranes of human spermatozoa: A rapid assay for detection of membrane changes after cryostorage. J Mol Hum Reprod 1999; 5: 109115.
  • 17
    Troeira Henriques S,Costa J,Castanho MARB. Translocation of β-galactosidase mediated by the cell-penetrating peptide Pep-1 into lipid vesicles and human HeLa cells is driven by membrane electrostatic potential. Biochemistry 2005; 44: 1018910198.
  • 18
    Geisow MJ,D'Arcy Hart P,Young MR. Temporal changes of lysosome and phagosome pH during phagolysosome formation in macrophages: Studies by fluorescence spectroscopy. J Cell Biol 1981; 89: 645652.
  • 19
    Sohrab S,Petrusca DN,Lockett AD,Schweitzer KS,Rush NI,Gu Y,Kamocki K,Garrison J,Petrache I. Mechanism of α-1 antitrypsin endocytosis by lung endothelium. FASEB J 2009; 23: 31493158.
  • 20
    Perlmutter DH,Joslin G,Nelson P,Schasteen C,Adams SP,Fallon RJ. Endocytosis and degradation of α1-antitrypsin-protease complexes is mediated by the serpinenzyme complex (SEC) receptor. J Biol Chem 1990; 265: 1671316716.
  • 21
    Neundorf I,Rennert R,Hoyer J,Schramm F,Löbner K,Kitanovic I,Wölfl S. Fusion of a short HA2-derived peptide sequence to cell-penetrating peptides improves cytosolic uptake, but enhances cytotoxic activity. Pharmaceuticals 2009; 2: 4965.
  • 22
    Modrykamien A,Stoller JK. Alpha-1 antitrypsin (AAT) deficiency—What are the treatment options? Expert Opin Pharmacother 2009; 10: 26532661.
  • 23
    Kalsheker NA. α1-Antitrypsin deficiency: best clinical practice. J Clin Pathol 2009; 62: 865869.
  • 24
    Gildea TR,Shermock KM,Singer ME,Stoller JK. Cost-effectiveness analysis of augmentation therapy for severe alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 167: 13871392.